SOLICITATION NOTICE
B -- Transfer and Refinement of Nuclease P1-Enhanced 32P-Postlabeling Chromatography Assay
- Notice Date
- 5/28/2003
- Notice Type
- Solicitation Notice
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Research Contracts Br., 6120 Executive Blvd. EPS Suite 600, Rockville, MD, 20852
- ZIP Code
- 20852
- Solicitation Number
- Reference-Number-NCI-30064-NV
- Response Due
- 6/3/2003
- Archive Date
- 6/18/2003
- Point of Contact
- Deborah Moore, Purchasing Agent, Phone (301) 402-4509, Fax (301) 402-4513, - Renita Smith, Contract Specialist, Phone 301-496-8612, Fax 301-480-0241,
- E-Mail Address
-
dm170b@nih.gov, rs442i@nih.gov
- Description
- The National Cancer Institute (NCI), Center for Cancer Research (CCR), Dermatology Branch, plans to procure on a sole source basis with Dr. Raghu Nath, Vienna VA 22182, to continue to apply the nuclease P1-enhanced 32P-postlabeling chromatography of Dr. Kurt Randerath for the detection of I-compounds in cultured cells from patients with various neurodegenerations. The Dermatology Branch has as one of its major interest human neurodegenerations caused by defective repair of DNA damage. Its been published that nerve cells likely die because of the accumulation of unrepaired oxidative DNA damage in several diseases. The Dermatology Branch is now trying to establish the presence of one or more of these unrepaired lesions in certain diseases. The lab has been and needs to continue to use Dr. Randerath's postlabeling assay to determine whether any oxidative lesion is repaired abnormally in diseased cells. This is the only assay that can detect structurally unknown oxidative lesions which may cause neurodegeneration. It can detect as few as 1-5 lesions per cell. Dr. Nath undertook his post-doctoral fellowship under Dr. Randerath and now that Dr. Randerath is no longer performing experiments Dr. Nath is the only trained source that can faithfully care out the Randerath postlabeling. This procurement is commercial as defined in FAR Part 2, and this acquisition is being made in accordance with the test program using simplified procedures for certain commercial items as authorized in FAR 13.5. This is not a request for competitive quotation. However, if any interested party believes it can meet the above requirement, with out the introduction of new variables into on going experiments it may submit a statement of capabilities. The statement of capabilities and any other information furnished must be in writing and must contain material in sufficient detail to allow the NCI staff to determine if the party can perform this requirement. An original and one copy of the capability statements must be received in the contracting office by 1:00 p.m. EDT, on June 3, 2003. All questions must be in writing and can be faxed to (301) 402-4513 or emailed to dm170b@nih.gov . It is the vendor's responsibility to call (301) 402-4509 to insure questions have been received. A determination by the Government not to compete this proposed requirement based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. No collect call will be accepted. NAICS 541990
- Place of Performance
- Address: Bethesda, MD
- Zip Code: 20892
- Zip Code: 20892
- Record
- SN00333281-W 20030530/030528213213 (fbodaily.com)
- Source
-
FedBizOpps.gov Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |